醋酸阿比特龙联合LHRH治疗对比醋酸阿比特龙同时保留LHRH治疗用于进展性转移性化疗初治去势抵抗性前列腺癌(SPARE):随机对照试验研究方案
SPARE试验为多中心、前瞻性、随机、探索性II期试验,纳入无症状或轻度症状、化疗初治的转移性去势抵抗性前列腺癌患者,随机分为开始阿比特龙/泼尼松时继续LHRH治疗组与停用LHRH组,主要评估治疗12个月后的影像学无进展生存期,并观察治疗下复杂激素变化及安全性,结果可能为更大规模III期试验提供依据。
要点
- 研究比较开始阿比特龙/泼尼松时继续LHRH治疗与停用LHRH的疗效和安全性
- 主要终点为治疗12个月后的影像学无进展生存期
- 纳入无症状或轻度症状、化疗初治的转移性去势抵抗性前列腺癌患者
核心结论
- 该试验将提供关于阿比特龙/泼尼松治疗联合或不联合继续LHRH治疗的疗效和安全性的新数据,并可能为在去势抵抗性前列腺癌患者中停用LHRH治疗的可能性提供依据以开展更大规模III期试验。
研究设计与样本
- 多中心、前瞻性、随机、探索性II期试验,纳入无症状或轻度症状、化疗初治的转移性去势抵抗性前列腺癌患者,随机分为继续LHRH治疗组与停用LHRH组。
主要发现
- 主要评估开始阿比特龙/泼尼松治疗12个月后的影像学无进展生存期,并进一步了解治疗下复杂的激素变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking. Argumentation for cessation of LHRH therapy is the prolonged suppression of testosterone levels after the withdrawal of LHRH analogues and the fact that disease progression occurs despite castration levels of testosterone. Especially upon treatment with the life-prolonging cytochrome P450 17-alpha-hydroxylase (Cyp17)-inhibitor, abiraterone, which has the ability to further suppress testosterone serum levels over LHRH therapy alone, continuation of LHRH therapy seems to be negligible. However, the proven increase of luteinizing hormone levels after LHRH withdrawal, which is even further increased by abiraterone, may counteract the effects of abiraterone by the induction of enzymes of steroidogenesis. Therefore, cessation of LHRH therapy when starting treatment with abiraterone in CRPC may display an unpredictable hazard to the patients. This study will explore the role of continuation of LHRH therapy when starting treatment with abiraterone in patients with asymptomatic or mildly symptomatic, chemotherapy-naïve CPRC. METHODS/DESIGN: The trial will assess radiographic progression-free survival after 12 months of treatment with abiraterone/prednisone in patients who will be randomized to receive continuing LHRH therapy versus LHRH withdrawal at the time of starting abiraterone therapy. DISCUSSION: This multicenter, prospective, randomized, exploratory phase-II trial will bring about new data regarding the efficacy and safety of abiraterone/prednisone treatment with or without continuation of LHRH therapy. In addition, further insight into the complex hormonal changes under treatment will be gained and the results of this trial may give rise to a larger phase-III trial to examine the possibility of withdrawing LHRH therapy in patients with CRPC. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02077634 . Registered on 9 December 2013.
引用
- Ohlmann CH, Jäschke M, Jaehnig P, et al. Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial. Trials. 2017. PMID: 28978327. doi:10.1186/s13063-017-2195-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。